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Cannabidiol (CBD), a non-euphorigenic compound derived from Cannabis, shows 
promise for improving recovery following cerebral ischemia and was recently effective for 
the treatment of childhood seizures caused by Dravet and Lennox-Gastaut syndromes. 
This condition is associated with developmental delays, including language deficits. In 
addition to clinical evidence of anti-seizure efficacy, quality of life assessments indicates 
improved cognitive function that includes speech. These reports suggest that CBD may 
have efficacy to improve vocal learning. Based on clinical observations, we hypothesize 
that CBD has distinct efficacy to mitigate CNS damage and promote vocal learning. To 
test this hypothesis, we have emplloyed a songbird, the male zebra finch, as a novel pre-
clinical animal model. To assess the efficacy of CBD to mitigate CNS damage, we used 
adult birds, which received bilateral microlesions of HVC (used as a proper name) a pre-
vocal motor cortical-like brain region that drives song learning. Moreover, to examine the 
efficacy of CBD to promote vocal learning, we used juvenile birds that received unilateral 
lesion of lMAN that plays a major role during the sensorimotor stage of vocal learning. 
Their songs were analyzed using Kullback–Leibler (KL) distance, syntax and production 
analysis to confirm the effects of CBD. Our results indicate that 10 and 100 mg/kg CBD 
 
 
effectively reduced the time required to recover vocal phonology and syntax. In the case 
of phonology, the magnitude of microlesion-related disruptions were also reduced. Also, 
our results demonstrated ability of CBD to improve vocal learning following damage to 
lMAN that plays a major role in vocal learning during sensorimotor stage. Treatment with 
10mg/kg CBD for 10 days improved vocal learning in terms of phonology and measures 
of syntax. These results suggest CBD holds promise to improve functional recovery of 
complex learned behaviors following brain injury and therapeutic promise for treatment of 
speech- and/or language-related disorders. In addition to demonstrating CBD efficacy, 
the work represents establishment of an important new animal model to screen drugs for 
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CHAPTER 1: INTRODUCTION 
1.1 Cannabis  
1.1.1 Cannabis use over thousands of years 
Over thousands of years, Cannabis has been used in many parts of the world for 
its effects to alter CNS activity. Before the sixth century BC, Cannabis was used by the 
Assyrians for its medical properties, as well as its psychoactive effects (Mechoulam and 
Parker 2013). In addition, in the Middle East, the use of Cannabis ever since has 
continued (Rosenthal 1971). In China, its dual effects were known and are documented 
in the Ben Ts’ao which is the Chinese pharmacopeia written in the first century AD. This 
source recommended Cannabis use for different diseases and noted problems with its 
euphoric effects when used in excess (Mechoulam and Parker 2013). The Napoleonic 
soldiers introduced Cannabis when to Europe they returned from Egypt (Rosenthal 1971). 
So, from that time virtually all civilized people have used Cannabis for its medical and 
euphoric effects.  
The psychological effects of Cannabis have been known since 1845 when Moreau 
in his book, Hashish and Mental Illness, documented associated hallucinations, 
delusions, errors of space and time, fluctuations of emotions and irresistible impulses 
(Moreau 1973). The medical use of Cannabis was not reliable in Europe, because the 
governments were worried about their psychological effects (Mechoulam and Parker 
2013). In addition, before 1960s, research on Cannabis was limited to a few groups of 
scientists (Mechoulam and Parker 2013). However, now with the great development in 
the field of research and the diversity of techniques, research has flourished on hashish, 




The genus Cannabis consists of three species, which have useful amounts of 
psychoactive cannabinoids: Cannabis indica, Cannabis ruderalis and Cannabis sativa 
(Ben Amar 2006).  Cannabis has more than 460 known compounds; and more than 60 
of these are cannabinoids structurally-related to the most psychoactive delta-9-
tetrahydrocannabinol (∆-9-THC) (Ben Amar 2006). Other notable cannabinoids include, 
cannabidiol (CBD), cannabinol (CBN), cannabicyclol (CBL), and cannabigerol (CBG); 
these have less psychoactive effects than ∆-9-THC, but still play a role in the effects of 
Cannabis (Gordon, Conley, and Gordon 2013). ∆-9-THC, CBD and CBN are the most 
studied cannabinoids (Gordon, Conley, and Gordon 2013). ∆-9-THC acts as a partial 
agonist for both Cannabinoid receptor type 1 (CB1) and Cannabinoid receptor type 2 
(CB2) (Gaston and Friedman 2017). CBD has no euphorigenic effects (Devinsky et al. 
2014). CBN is a degradation product of Delta-9-tetrahydrocannabinol and has a moderate 
psychotropic effect (Gordon, Conley, and Gordon 2013). In humans, the CB1 receptors 
are mainly found in the central nervous system (CNS) and the CB2 receptors are mainly 
found in peripheral tissue, including cells involved in inflammation and immunity (Gaston 
and Friedman 2017). Because of these receptors, Cannabis products have diverse 
effects in different systems. 
1.1.2 Medical uses 
Medical Cannabis has many potential beneficial effects such as helping 
in reducing chronic pain and attenuating muscle spasms (Whiting et al. 2015). In addition, 
it is effective in reducing nausea and vomiting during chemotherapy, improving sleep, 
improving tics in Tourette syndrome and improving appetite in HIV/AIDS (Whiting et al. 




glaucoma (Sachs, McGlade, and Yurgelun-Todd 2015). The legal use of marijuana is 
increasing. In the USA: 35 states have legalized marijuana use for medical purposes 
(National Conference of State Legislatures 2019) 
1.2 Endocannabinoid system 
The main effects of cannabinoids are produced through the endocannabinoid 
system. The endocannabinoid system consists of the cannabinoid receptors (mainly CB1 
and CB2 receptors), their endogenous agonists: the endocannabinoids (ECs)  
anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG), 
and the enzymes responsible for their synthesis, degradation and uptake (Szabo and 
Schlicker 2005). 
1.2.1 The Cannabinoid Receptors: 
1.2.1.1 The CB1 Receptor 
In humans, the CB1 receptors are mainly found in the central nervous system 
(CNS) (Gordon, Conley, and Gordon 2013). CB1 receptors are the most abundant 
GPCRs (G protein-coupled receptors) in the brain (Mackie 2006). In addition, they are 
expressed in the sensory and motor regions consistent with the important role of CB1 
receptors in motivation and cognition (Mechoulam and Parker 2013). CB1 is activated 
by: endocannabinoids, such as AEA and 2-AG; plant phytocannabinoids, such as the 
compound ∆-9-THC which, as noted above, is the principal active constituent 
of Cannabis; or synthetic compounds such as Nabilone; and  several compounds related 
to carboxamide (Mechoulam and Parker 2013). 
The CB1 receptors are found primarily on the presynapse of central and peripheral 




neurotransmitter release, which is one of the functions of the endocannabinoid system. 
Most CB1 receptors are coupled through Gi/o proteins (Mechoulam and Parker 2013). 
Activation of CB1 receptors causes reduced accumulation of cyclic adenosine 
monophosphate (cAMP) and this leads to inhibition of cAMP-dependent protein kinase 
(PKA) (Mechoulam and Parker 2013). In addition, CB1 receptor activation leads to 
stimulation of mitogen-activated protein (MAP) kinase activity, which is a mechanism by 
which cannabinoids affect synaptic plasticity, cell migration, and possibly neuronal growth 
(Howlett et al. 2002). CB1 receptors are also coupled to several types of calcium and 
potassium channels (Mechoulam and Parker 2013). The expression of these kinds of 
coupled receptors has an effect on myelin sheath formation, that might help to treat some 
demyelinating diseases such as multiple sclerosis (Mato et al. 2009). 
1.2.1.2 The CB2 Receptor 
In humans, the CB2 receptors are mainly found in the immune system cells 
(Mechoulam and Parker 2013) such as monocytes, B-cells, macrophages, and T-cells 
(Basu, Ray, and Dittel 2011). Similar to the CB1 receptors, CB2 receptors produce their 
effect by inhibition of the activity of adenylyl cyclase (AC) through activation of 
Gi/Goα subunits (Demuth and Molleman 2006). CB2 receptor expression under 
pathological conditions is activated to mediate immunosuppressive effects and enhance 
neuroprotection (Pacher and Mechoulam 2011). 
1.2.2 Endogenous Cannabinoid Ligands 
The discovery of the CB1 and CB2 receptors suggested that endogenous 
cannabinoids are presumably present in the human body because the constituents of 




group worked to identify some endogenous molecules that act on these receptors. In 
1992, Mechoulam’s group isolated a compound from brain, which they named 
anandamide (AEA) (Devane et al. 1992). In addition, in 1995 they also isolated and 
identified a second compound from peripheral tissue that they named 2-arachidonoyl 
glycerol (2-AG) (Mechoulam et al. 1995). The structures of these two compounds are 
shown in Figure 1.1. Then, scientists started investigating the effects of these 
endogenous cannabinoids. Unlike other neurotransmitters, such as acetylcholine, 
serotonin, and dopamine, these two endogenous cannabinoids are not stored in vesicles, 
but are synthesized when they are needed (Mechoulam and Parker 2013). Moreover, 
their action is mostly presynaptic not postsynaptic like most neurotransmitters 
(Mechoulam and Parker 2013). 
After synthesis of anandamide and 2-arachidonoyl glycerol in postsynaptic 
neurons, they cross the synapse to activate the cannabinoid presynaptic receptor that 
inhibits release various of  neurotransmitters (Howlett et al. 2002). This is the main role 
of the endocannabinoids (Mechoulam and Parker 2013). Inside the cell, anandamide is 
hydrolyzed by fatty acid amide hydrolase (FAAH) to arachidonic acid and ethanolamine 
(Wilkerson et al. 2017). 2-arachidonoyl glycerol is hydrolyzed by Monoacylglycerol lipase 
(MAGL) to arachidonic acid (Wilkerson et al. 2017) (see Figure 1.2). Inhibition of these 
enzymes prolongs the activity of these endocannabinoids (Mechoulam and Parker 2013). 
1.3 Cannabidiol 
The two most abundant psychoactive components in Cannabis are the 
euphorigenic ∆-9-THC and the non-euphorigenic (CBD). The term of non-euphorigenic 




psychoactive effects including anti-anxiety, anti-depressant and other behavioral effects 
(Devinsky et al. 2014). In addition to the advantage of non-euphorigenic effects of CBD, 
this drug is currently of great interest because it has many effects and multiple 
pharmacological targets. In the last few decades, there are many studies that have 
investigated CBD effects finding that CBD attenuates damage of  the brain following 
ischemic and/or neurodegenerative conditions (Devinsky et al. 2014; ElBatsh et al. 2012). 
Also, it has positive effects in many neuropsychiatric disorders such as anxiety and 
depression (ElBatsh et al. 2012; Almeida et al. 2013; Bergamaschi et al. 2011; Devinsky 
et al. 2014). Moreover, CBD has anti-inflammatory, neuroprotective, and antiepileptic 
effects (Devinsky et al. 2014a).  
The mechanisms of action of CBD to produce these effects are still unclear, but 
many observations suggest it can act as an agonist at the 5-HT1A receptor and through 
which it produces anxiolytic effect (Gomes, Resstel, and Guimarães 2011; Connors et al. 
2014) and reduces neuropathic pain (Palazzo et al. 2006). Also, it binds with α3 and α1 
glycine receptors (Pertwee 2008) which may lead to reduced schizophrenic symptoms 
(Devinsky et al. 2014). CBD has also been shown as an antagonist at the orphan G-
protein-coupled receptor GPR55 (Devinsky et al. 2014) and based on some studies 
antagonizing this receptor will play a role to reduce inflammation (Montecucco et al. 
2016). In addition, CBD enhances adenosine A1 receptor activity via blocking 
equilibrative nucleoside transporter activity (ENT) (Devinsky et al. 2014), which will 
produce anti-inflammatory effects (Carrier, Auchampach, and Hillard 2006). CBD has a 




In addition to these target sites, CBD is effective against maximal electroshock (MES) 
and pentylenetetrazole (PTZ)-induced seizures (Devinsky et al. 2014). 
1.3.1 Potential Clinical Implications  
During recent years, there have been many important clinical trials done to study 
the potential effects of CBD in pain management. A combination of CBD and Δ-9-THC 
has significantly reduced acute pain scores in postoperative patients (Holdcroft et al. 
2006), as well as reduced chronic pain associated with rheumatoid arthritis, multiple 
sclerosis, peripheral neuropathy, and central neuropathic pain (Zajicek et al. 2003; Rog 
et al. 2005). In Canada, Sativex®, a combination of CBD and Δ-9-THC (1:1 ratio), was 
approved to treat neuropathic pain in patients suffering from multiple sclerosis and in 
cancer patients as an adjunctive analgesic medication. In addition, Cannador®, 
containing CBD and Δ-9-THC in a 2:1 ratio, was registered in different countries and used 
in several clinical trials to reduce spasms, muscle stiffness, and pain in multiple sclerosis 
(Holdcroft et al. 2006). Moreover, other clinical trials have been investigating the effect of 
CBD-enriched Cannabis as a therapy to treat certain types of epilepsies such as Dravet 
syndrome (DS) and Lennox-Gastaut syndrome (LGS). Results showed a reduced seizure 
frequency in both DS (Devinsky et al. 2017) and LGS patients (Devinsky et al. 2018; 
Thiele et al. 2018). Additionally, several parents of these patients reported improved 
alertness without side effects such as drowsiness and fatigue, that are associated with 
current antiepileptic drugs (Devinsky et al. 2014; Oakley, Kalume, and Catterall 2011). 
Because of these positive effects of CBD, Food and Drug Administration (FDA) approved 




In addition, CBD has a positive effect on schizophrenic patients. One clinical trial 
compared a standard antipsychotic, amisulpride, and CBD to reduce acute schizophrenia 
in 33 patients on a timeline of more than four weeks. Both drugs showed similar significant 
improvements (Leweke et al. 2012). However, CBD produces its effect without 
amisulpride’s side effects, such as extrapyramidal symptoms, elevated serum prolactin, 
and weight gain (Leweke et al. 2012). Furthermore, according to several human and 
animal studies, CBD has anxiolytic effects (Devinsky et al. 2014). A recent study 
confirmed an anxiolytic effect in patients with social anxiety disorder using CBD whereby 
patients have shown changes in blood flow in both paralimbic and limbic brain regions 
(Crippa et al. 2011). Furthermore, several studies found that CBD to attenuate brain 
damage following ischemic and/or neurodegenerative conditions (ElBatsh et al. 2012; 
Devinsky et al. 2014). 
1.3.2 Pharmacokinetics 
CBD is a highly lipophilic compound with a high volume of distribution, 
approximately 32 L/kg, and rapid distribution into the adipose tissue, brain and other 
organs (Devinsky et al. 2014). It has also been estimated with high protein binding and it 
may accumulate in adipose tissue especially in chronic administration (Devinsky et al. 
2014). Similar to most cannabinoids, the metabolism of CBD occurs in the liver where it 
is hydroxylated by the CYP2C (8/9/19) CYP3A (2/4) to form OH-CBD (Devinsky et al. 
2014). After further metabolism, the metabolites are excreted in the feces and urine and 




1.3.2.1 Adverse events 
In humans, multiple studies of CBD safety have shown that CBD is well tolerated 
in a wide dosage range. It does not produce significant side effects in terms of the central 
nervous system, does not have significant effects on vital signs or changing mood, having 
been studied at doses of up to 1500 mg/day (orally) or 30 mg (intravenously) in acute and 
chronic administration (Bergamaschi et al. 2011).  A study of Thiele et al. shows that CBD 
produces some side effects such as vomiting, pyrexia, loss of appetite, somnolence, and 
diarrhea (Thiele et al. 2018). In addition CBD inhibited production of Interleukin 8 and 10 
to induce apoptosis of lymphocytes in vitro (Srivastava, Srivastava, and Brouhard 1998; 
Wu et al. 2008).  
Based on screening of Devinsky et al., most of the studies were done in adults 
(Devinsky et al. 2014). Therefore, more studies need to assess the CBD 
pharmacokinetics and toxicity in children. 
1.3.3 CBD, neuroprotection and neuropsychiatric disorders 
 Millions of people in the world are suffering from neuropsychiatric disorders such 
as anxiety, depression, schizophrenia (World Health Orgnization 2018). These disorders 
are among the most complex medical conditions that cause incapacity (Department of 
Health Statistics and Information Systems and WHO 2013). Although these 
neuropsychiatric disorders are caused by several interaction factors, such as the 
environment, medications and genes (ROY et al. 2014; Levinstein and Samuels 2014), 
the specific etiology of these disorders are not well understood which causes patients to 




Within the last few years, many researchers have worked to find new therapeutic 
targets for these neuropsychiatric disorders and focused on the neuroplastic cellular 
processes to treat or reduce symptoms of these disorders through neuroprotective 
mechanisms such as oxidative stress, neurotrophic factors and immune mediators 
(Kalivas and O’Brien 2008; Alline C. Campos et al. 2016; Bredt et al. 2015).  
CBD shows a large spectrum of potential therapeutic properties in animal models 
as well as in humans, including antidepressant, antianxiety (A. C. Campos et al. 2012; A. 
W. Zuardi et al. 1993), anti-inflammatory (Mori et al. 2016; Shimon Ben-Shabat et al. 
2006), neuroprotective (A. C. Campos et al. 2012) and immunomodulatory (Kozela et al. 
2010). Moreover, CBD reduces the inflammatory cytokines production and activation of 
microglial cells (Napimoga et al. 2009; Kozela et al. 2011).  
Compared with other cannabinoids like THC, CBD has a better safety profile. For 
example high doses of CBD (reaching 1500 mg/day) are well tolerated in experimental 
animals and humans (Bergamaschi et al. 2011). It does not alter blood pressure, 
temperature of the body, heart rate, or produce catalepsy (Bergamaschi et al. 2011).  
Therefore, it has better safety profile, possibly because it does not have a direct effect at 
cannabinoid receptors (Scuderi et al. 2009). 
The mechanism of action for CBD to produce these potential neuroprotective 
effects, particularly in neuropsychiatric disorders are still unclear; however, it may be due 
to its multiple pharmacological targets (Alline C. Campos et al. 2016). 
1.3.3.1 The endocannabinoid system  
Several cannabinoid agonists were shown to enhance neuroprotection through 




Although many in vitro studies found that CBD has a low affinity for these receptors 
(Pertwee 2008), some effects of CBD seem to have an impact on these receptors. These 
effects may be through an increase of anandamide level by inhibition of its 
metabolism/uptake (Bisogno et al. 2001; Alline Cristina Campos et al. 2013). In addition, 
AM251, the inverse agonist of CB1 receptor, blocked the effects of CBD in conditioned 
fear on extinction and reconsolidation (Stern et al. 2012). Moreover, The CB2 receptor 
inverse agonist AM630, attenuated CBD effects on reducing acute and apoptotic brain 
damage through effecting on production of TNF-,COX-2 and IL-6 (Castillo et al. 2010).  
1.3.3.2 5HT1A receptors  
Previous studies suggested that CBD produces many effects through interaction 
with serotonin receptors (Resstel et al. 2009; Fogaça et al. 2014). Until now there are 
seven types of serotonin receptors have been discovered: six of them are G-protein 
coupled and one iontropic. The 5HT1 type is Gi/o protein coupled and have five subtypes: 
5HT1A, 5HT1B, 5HT1D, 5HT1E, and 5HT1F. These receptors are located in pre-synaptic 
membranes and also present post-synaptically in many brain regions (European 
Behavioural Pharmacology Society et al. 1997). According to the opinion of Fernández-
Ruiz et al is that the main receptor that produces neuroprotective effect of CBD is 5HT1A 
(Fernández-Ruiz et al. 2013). As Compos et al. and Resstel et al. have indicated CBD 
produces anxiolytic effects by activation of 5HT1A receptors (Alline Cristina Campos et al. 
2013; Resstel et al. 2009). In addition to anxiolytic effects, a study by Linge et al. shows 
that CBD induced antidepressant effects by working as an agonist at these receptors 
(Linge et al. 2015).The neuroprotective effects of CBD has also been linked with 5HT1A-




antagonist prevented CBD reduction of damage in brain tissue caused by cerebral artery 
occlusion (Hayakawa et al. 2007; Mishima et al. 2005). 
1.3.3.3 Oxidative stress and peroxisome proliferator-activated receptor gamma (PPARᵞ)  
Oxidative stress is described as an imbalance between the production of free 
radicals and the ability of the organism to detoxify their effects by producing antioxidants 
(Alline C. Campos et al. 2016). The production of free radicals such as reactive 
oxygen/nitrogen species (ROS/RNS) can be unsafe to the human body because these 
compounds are very reactive with other compounds inside the body and will negatively 
impact fatty acids, proteins, and DNA leading to cellular death (Niedzielska et al. 2016; 
Pisoschi and Pop 2015). 
Cannabidiol has a polyphenolic nature (see Figure 1.1) making CBD a potent 
antioxidant. Moreover, many studies show CBD reduced tyrosine nitration, 
malondialdehyde (MDA) levels and decreased apoptosis and neural cell death (El-
Remessy et al. 2003, 2006). In addition, CBD produces antioxidant effects through 
reducing ROS accumulation, caspase-3 levels, lipid peroxidation, and DNA fragmentation 
in Alzheimer disease and multiple sclerosis models (Iuvone et al. 2004). Moreover, CBD 
reduces production of ROS cell death induced by hydrogen peroxide (H2O2) (Mecha et 
al. 2012). Beside the effect of CBD on ROS production, CBD activates peroxisome 
proliferator-activated receptor gamma (PPARᵞ) which has an effect to reduce cellular 
proliferation, apoptosis and reduction of damage induced by free radicals (Rodrigues et 




1.3.3.4 Immune mediators, BDNF, and other related mechanisms  
The beneficial effects of CBD on neuropsychiatric disorders have also been 
associated with its effect on pro-inflammatory cytokines and brain-derived neurotrophic 
factor (BDNF) expression. Low brain levels of BDNF and excess pro-inflammatory 
cytokines were associated with poor cognitive performance (Alline C. Campos et al. 
2016). These effects were reduced by CBD treatment (Barichello et al. 2012). In addition, 
CBD decreased activation of microglia in models of Alzheimer’s disease and 
schizophrenia (Gomes et al. 2015; Mecha et al. 2013). CBD also decreased release  of 
IL-6 and IL-17, which reduced the severity of experimental autoimmune 
encephalomyelitis (EAE) (Campos et al. 2016)  
1.3.3.5 Inhibition of adenosine uptake 
Activation of adenosine signaling, by increasing extra-cellular levels of adenosine 
(Mijangos-Moreno et al. 2014), was suggested to mediate part of CBD effects such as 
anti-inflammatory, immunosuppressive and neuroprotective (Carrier, Auchampach, and 
Hillard 2006). In addition, the work of Mechaet al. shows antagonists of the A2A receptor 
prevented CBD neuroprotective effect (Mecha et al. 2013).  
These mechanisms of CBD clearly indicate that CBD can be a new opportunity to 
treat several brain disorders.  
1.3.4 CBD in Dravet and Lennox-Gastaut syndromes 
Dravet and Lennox-Gastaut syndromes are rare, genetic forms of childhood 
epilepsy and associated with developmental delays (Devinsky et al. 2016). Both start in 
the first year of life and are difficult to treat (Devinsky et al. 2016). CBD has recently been 




et al. 2018; Thiele et al. 2018a) and drug-resistant seizures in children afflicted with Dravet 
syndrome (Devinsky et al. 2017). This places CBD among the few treatments useful in 
these conditions. In addition to seizures, children with Dravet syndrome also typically 
suffer from cognitive impairment and developmental delays (Dravet and Oguni 2013). 
Although not yet supported by controlled clinical studies, survey-based quality of life 
assessments suggest that CBD treatment, in addition to having anti-seizure efficacy, may 
also mitigate associated cognitive deficits, and improve social interaction (Rosenberg et 
al. 2017). 
1.4 Vocal defect disorders 
According to Morris et al. about 17.9 million adults have difficulty using their voice 
in the US (Morris et al. 2016). In addition, 9% of young children have speech sound 
disorder (National Institute on Deafness and Other Communication Disorders (NIDCD) 
2016). Because a defect in vocal production can give rise to different effects, such as 
impaired social development and social interactions, more research should be focused 
on improving vocal learning (Fusaroli et al. 2016). There are many disorders that cause 
or are associated with vocal defects including stroke and autism (Özbal Koç et al. 2016; 
Mayo clinic staff 2015).  
Globally, approximately 21.7 million people have autism disorder in 2013 (Global 
Burden of Disease Study 2013 Collaborators 2015). In the United States, about one in 68 
children (about 1.5%) were diagnosed with autism in 2014, and in 2012 was one in 88 
children (Autism and Developmental Disabilities Monitoring Network Surveillance Year 
2008 Principal Investigators and Centers for Disease Control and Prevention 2012; 




learning defect (Condro and White 2014; Panaitof 2012) and about 50% or more of these 
patients displayed early abnormal acoustic patterns (Fusaroli et al. 2016; Paul et al. 2005; 
Rogers et al. 2006; Shriberg et al. 2001). In addition to autism, vocal defects can be 
caused by stroke that occludes blood flow to the part of the brain that is responsible for 
activating the larynx (Özbal Koç et al. 2016; Mayo clinic staff 2015; NIH 2015; Ito et al. 
2008). Consequently, the need to find a drug to combat this disorder is highly desired. 
This project investigated the effects of CBD, and how it `mitigates CNS damage and 
improves vocal learning. 
1.5 Zebra Finch Model 
 The zebra finch songbird is a good model for the study of auditory and speech 
disorders for many reasons: in a manner similar to humans, male zebra finches learn how 
to produce a form of vocal communication (Scharff and Nottebohm 1991). Both species 
must learn their respective forms of communication from the sounds of adults of the 
species (Doupe and Kuhl 1999). In the case of a human, a baby will listen to the parents, 
and after a few months, he will start to talk. A similar process occurs with baby zebra 
finches; he will listen to his tutor, and after few weeks, he will start to sing. Also, both 
species use their auditory system as well as their vocal motor production of song to learn 
to vocalize (Doupe and Kuhl 1999; Brainard and Doupe 2002). In addition, both the zebra 
finches and humans have vocal learning and motor brain pathways (Nottebohm 2005; 
Simmonds 2015). The learning and production of bird song involves distinct brain areas 
that are divided into two pathways: a vocal learning pathway and a vocal motor pathway 
(Simmonds 2015). The vocal learning pathway involves these areas: lMAN, Area X , and 




2005; Simmonds 2015). Similar to the birds, humans have vocal learning and vocal motor 
pathways that are involved in learning and producing vocalizations (Simmonds 2015). 
The vocal learning pathway involves these areas: cortex, striatum, and thalamus.  The 
vocal motor pathway involves these areas: premotor cortex and motor cortex (Simmonds 
2015) ( see Figure 1.3) .In conclusion both species have similarity in using their auditory 
system, listening to a tutor for vocal learning, having vocal learning and motor brain 
pathways and have similar neuronal circuits. For these reasons, the zebra finch is a good 
candidate to test the hypotheses of this project.  
1.5.1 Neural pathways in the song system  
Neural pathways in the bird’s song system starts from (vocal motor pathway) HVC, 
which sends a message to the (vocal learning pathway) Area X and RA  in vocal motor 
pathway. In the vocal motor pathway, a message goes to RA from HVC, then from RA, 
the message will travel to the hypoglossal nerve (nXIIts), which controls muscles of the 
syrinx. After the completion of the neural pathways, the song of the bird will be produced 
(Mooney 2009; RODERICK A. SUTHERS 2004). Whereas in the vocal learning pathway, 
a message is sent from HVC to Area X, then to the DLM, then it will reach to lMAN, after 
that vocal motor pathway will receive the message from lMAN through RA (Mooney 2009; 
RODERICK A. SUTHERS 2004). According to previous studies, when birds are young, 
lMAN plays a large role in controlling activity in RA and is essential for birds to learn song 
(Scharff and Nottebohm 1991). As learning is completed, HVC assumes primary control 





1.6 Goal of Research and Statement of Hypothesis 
About 17.9 million adults and 9% of young children have difficulty using their voice 
in the US (National Institute on Deafness and Other Communication Disorders (NIDCD) 
2016). This defect can be caused by or associated with some diseases such as stroke, 
trauma and autism (Godoy et al. 2014; Mayo clinic staff 2015; Özbal Koç et al. 2016).  In 
addition, children with Dravet syndrome typically suffer from cognitive impairment and 
developmental delays which are associated with vocal defects (Dravet and Oguni 2013). 
Moreover, a vocal production and learning defect can give rise to other problems including 
impaired social development and interaction (Fusaroli et al. 2016). Consequently, the 
need to find a drug to combat this disorder is highly desired.  
Moreover, survey-based quality of life assessments suggests that CBD treatment, 
in addition to having anti-seizure efficacy, may also mitigate associated cognitive deficits, 
and improve social interaction (Rosenberg et al. 2017). Importantly, quality of life 
assessments also suggests improved language, but better efficacy in children with 
families that relocated for treatments indicate a contributing placebo effect (Press, Knupp, 
and Chapman 2015). In addition to this observation, anxiolytic effects of CBD which will 
help to reduce stress that might be helping to improve vocal learning. Therefore, these 
effects as well as other effects such as anti-inflammatory and antioxidant effects will 
support the hypothesis of this project that CBD has distinct efficacy to mitigate CNS 
damage and promote vocal learning using zebra finches as a model. Stereotaxic 
techniques were used to make electrolytic lesions. This electrolytic lesions will target  
HVC to disrput vocal motor pathways and lMAN to make a defect in vocal learning. Then, 




Specific Aim 1: To determine whether CBD has distinct efficacy to mitigate CNS 
damage. The working hypothesis is that CBD will speed recovery time of song and will 
reduce the extent of phonetic change after a partial lesion of the pre-motor brain region, 
HVC. In effort to identify the effect of CBD on CNS damage, three different types of songs 
analyses were measured: KL distances analysis was used to assess the effect of CBD to 
improve acoustic features, the sequence analysis was measured to investigate the ability 
of CBD to improve syntax and production analysis was used to assess vocal motor 
activity.  
Aim 2: To evaluate whether CBD has an impact to promote vocal learning. Our 
working hypothesis is that CBD will enhance normal vocal learning as well as improve 
vocal learning following unilateral lMAN lesions. We will measure the effects of CBD using 
K-L distance measures, sequence analysis and production analysis in order to know if 
CBD has ability to improve vocal learning.   
At the completion of this study, we will have further understanding of the effects of 
CBD to improve recovery following damage to a pre-vocal motor brain region. This may 
help us to develop a new therapeutic intervention for treatment of speech- and/or 
language-related disorders. In addition to demonstrating CBD efficacy, the study will 
provide a pre-clinical animal model suitable for evaluation of drugs that modulate vocal 





Figure 4.1: Structures of the phytocannabinoids Δ-9-tetrahydrocannabinol and 















Figure 1.2: Endocannabinoid hydrolysis. 
In the nervous system, anandamide is degraded primarily by FAAH to produce 
arachidonic acid and ethanolamine, and 2-AG is degraded primarily by MAGL to produce 










Figure 1.3: Vocal motor and learning pathways on human and zebra finch.  
(i) The learning and production of a bird song involves distinct brain areas that are divided 
into two pathways: a vocal learning pathway and a vocal motor pathway. The vocal 
learning pathway (shown in blue) involves these areas: lMAN, Area X, and DLM whereas 
the vocal motor pathway (shown in green) involves these areas:  HVC, RA and brainstem 
nucleus for vocal output. (ii) Similar to the bird, humans have vocal learning and vocal 
motor pathways that are involved in learning and producing vocalizations. The vocal 
learning pathway (shown in blue) involves these areas: anterior striatum, thalamus and 
premotor cortex.  The vocal motor pathway (shown in green) involves these areas: 







CHAPTER 2: CANNABIDIOL IMPROVES VOCAL LEARNING-DEPENDENT 
RECOVERY FROM, AND REDUCES MAGNITUDE OF DEFICITS FOLLOWING 
DAMAGE TO A CORTICAL-LIKE BRAIN REGION IN A SONGBIRD PRE-
CLINICAL ANIMAL MODEL 
2.1 Introduction 
Cannabidiol (CBD) is one of many molecules derived from Cannabis that is 
structurally-related to the principal eurphorigenic cannabinoid, 9-tetrahydrocannabinol 
(THC). Although not associated with euphoria like THC, CBD is clearly psychoactive and 
is known to interact with many cellular macromolecules expressed within CNS (reviewed 
by Ibeas Bih et al., 2015; Soderstrom et al., 2017).  
CBD was recently demonstrated as effective for the treatment of Lennox-Gastaut 
syndrome (Devinsky et al., 2018; Thiele et al., 2018) and drug-resistant seizures in 
children afflicted with Dravet syndrome (Devinsky et al., 2017). This places CBD among 
few treatments useful in these conditions. In addition to seizures, children with Dravet 
syndrome also typically suffer from cognitive impairment and developmental delays 
(Dravet and Oguni, 2013). Although not yet supported by controlled clinical studies, 
survey-based quality of life assessments suggest that CBD treatment may also mitigate 
associated cognitive deficits, and improve social interaction including language (Press, 
Knupp, and Chapman 2015; Rosenberg et al. 2017). 
In addition to reports of improved cognition in children with seizure disorders, 
accumulating evidence indicates that CBD improves function in models of Alzheimer’s 




et al. 2016). Combined, this evidence suggests CBD may have distinct neuroprotective 
efficacy to promote recovery of complex behaviors following CNS disruption. In order to 
test this hypothesis, a songbird model has been applied. Songbirds, like the zebra finch, 
are among few vocal learning animals and are the only species well-suited to laboratory 
use (Petkov and Jarvis, 2012). Because song is complex and must be learned, the 
songbird model provides a means to evaluate drug effects on a behavior that depends 
upon higher brain function.  
In adult zebra finches, electrolytic destruction of a small part (about 10%) of the 
cortical-like pre-motor region HVC (proper name, see Figure 1A) results in a temporary 
disruption of vocal patterns that recover over about seven days (Thompson and Johnson, 
2007). Recovery from microlesions depends upon the ability of birds to hear, as deafened 
birds do not regain ability to produce typical song patterns (Thompson et al., 2007). 
Hearing-dependence indicates recovery requires auditory feedback necessary for adult 
sensorimotor vocal learning. Thus, the model allows assessment of learning-dependent 
recovery of a cognitively-complex behavior following CNS disruption – and evaluation of 
potential drug effects on this process. Further application of this model will allow the 
mechanism(s) of CBD action to be elucidated with potential relevance to positive cognitive 
effects reported in seizure trials.  





Unless otherwise indicated, all materials and reagents were purchased from Sigma 
or Fisher. CBD was provided as a >95% pure crystalline powder by GW Research Ltd, 
Cambridge, UK. The 5-HT1A–selective antagonist WAY-100,635 (WAY) was purchased 
from Tocris, USA. CBD was suspended in vehicle from 10 mM ethanol stocks. Vehicle 
consisted of a suspension of 2:1:17 Ethanol:Alkamuls EL-620 (Rhodia, Cranberry, 
NJ):phosphate-buffered saline. Daily ethanol dosages were 0.33 mg/kg - lower than that 
voluntarily consumed (Olson et al., 2014). WAY was diluted from a 10 mM stock in water 
and diluted for injection in sterile PBS.  
2.2.2 Experimental design 
The treatment plan is summarized in Figure 1B. Experiments spanned twenty 
days. During the first three recording days, no treatments were given. Pre-treatment 
recordings were used to generate baseline measures to which later daily recordings could 
be compared. After baseline recordings, once daily treatments began in the morning in a 
volume of 50 l IM to pectoralis. Six daily treatments were given prior to surgical 
procedures for two reasons: (1) to assess potential for CBD administration without other 
interventions to alter vocal behavior, and (2) in an effort to allow CBD, a lipophilic drug 
with large volume of distribution and elimination half-life, to approximate steady-state 
levels (Gamble et al. 2018). Surgeries were done on day 10 and treatments and 




2.2.3 Animals and audio recording environment  
Adult male zebra finches (>90 days of age) were raised in our breeding aviary and 
maintained at 78°F on a 12/12 light/dark cycle. They were individually housed in standard 
finch cages (9”x11”x17”) placed within recording chambers with ad libitum food and water. 
Chambers were fitted with individual microphones and lights. Birds were visually isolated 
while continuously recorded. Sound Analysis Recorder software (Tchernichovski et al., 
2000) was used to record vocalizations and store in Waveform Audio File (WAV) format. 
Birds were placed in recording chambers several days (3 to 5) prior to experiments. 
Animals not producing at least 500 song bouts per day during the last three habituation 
days were excluded. All animal procedures were approved by the East Carolina 
University Animal Care and Use Committee. 
Intended group numbers were n=6 animals per treatment (vehicle, 1, 10, 100 
mg/kg CBD and 0.1 mg/kg WAY + 10 mg/kg CBD, Figure 1C) and surgery condition 
(Microlesion, Sham and No-microlesion). One of the 10 mg/kg CBD animals in the 
microlesion group had lesion extent = 1.9%, exhibited minimal, sham-like effects on vocal 
behavior, and was therefore removed from the study (n=5). The 5-HT1A receptor 
antagonist WAY was used in an attempt to reverse CBD effects. This was done because 
evidence suggests that CBD acts, at least in part, through agonism of the 5-HT1A receptor 
in other systems (Resstel et al. 2009; Russo et al., n.d.). Only microlesion group animals 
received the combined 0.1 mg/kg WAY + 10 mg/kg CBD drug treatment (n=6). 




5-7 syllables) and motif complexity did not differ significantly across the five treatment 
groups (1-way ANOVA, F(4,24)=0.10, p=0.99).  
2.2.4 Microlesion surgeries 
Bilateral HVC microlesions were made following the procedure previously 
described (Thompson et al., 2007) except that animals were administered the anti-
inflammatory drug meloxicam (1 mg/kg) prior to procedures and were anesthetized with 
isoflurane. Birds were secured in a stereotaxic instrument and the bifurcation at the 
midsagittal sinus was used as stereotaxic zero. Small craniotomies were placed over 
HVC bilaterally. For approximately 10% destruction of HVC, four locations were targeted: 
2.4 and 2.8 mm bilaterally from stereotaxic zero to a depth of 0.6 mm. Microlesions were 
made with 100 A for 35s. Birds recovered in a warm incubator and were returned to 
recording chambers. Sham-group animals were subjected to all of the steps described 
above (including anesthesia, craniotomies and suturing) except no current was passed. 
No-microlesion group animals were transported to the operating room without other 
manipulation. 
2.2.5 Lesion extent 
Following final recordings, animals were overdosed with Equithesin. Brains were 
fixed with 4% paraformaldehyde, blocked down the midline and both hemispheres 
sectioned through HVC at 40 m. Sections were Nissl stained and those containing HVC 
were imaged at 40X. Lesion damage extent was calculated by tracing borders of both 




the infarct were summed and percent lesion extent expressed as infarct area divided by 
HVC area x 100%. 
2.2.6 KL distance measures of phonology 
Animals were recorded continuously over the entire 20-day experimental period. 
Recording files were input to Sound Analysis Pro 2011 software (SAP, Tchernichovski et 
al., 2000) to segment song bouts into their separate syllable components (uttered sounds 
separated by silence). Segmentation was accomplished by thresholding based upon 
amplitude, entropy, syllable and syllable gap durations. Thresholding was optimized for 
each animal, all other procedures were done objectively. Others have reported (Wu et al., 
2008) and we confirm that analyses of fewer than approximately 300 syllables is 
associated with underestimated phonology quality. Syllable numbers rarely reached 300 
on microlesion days and so these days were excluded from analyses. Other days not 
meeting this criteria (typically due to recording equipment malfunction) were also 
excluded.  
SAP characterizes individual syllables by their spectral structure through 
measures of acoustic features (e.g. syllable duration, amplitude, pitch, etc.) Acoustic 
feature measures were used to assess phonology via calculation of Kullback-Leibler (KL) 
distances using the methods developed by (Daou et al., 2012; Wu et al., 2008) that 
compare distances between 2D probability distributions of vocal acoustic features. 
Greater KL distance measures reflect increased phonological divergence across the 
vocalizations compared. We used acoustic measures from baseline recordings (days 1–




individual “targets”. KL distances between template and target distributions were 
calculated using software we developed (KLFromRecordingDays available as described 
in (Soderstrom and Alalawi, 2017). Because baseline days were used as the template, 
KL distances for this period = 0, and higher values observed on following days represent 
phonological divergence from baseline measures. Significant KL distance measure 
outliers, detected by the method described by Grubbs, 1969, were excluded from 
statistical analysis. 
2.2.7 Typical syllable transition measures of syntax 
Syntax was measured from the frequency of typical syllable transitions that were 
calculated using SongSeq software according to the method described by Daou et al., 
2012. SongSeq uses data exported from SAP to identify distinct syllables. Pre-treatment 
day three was used as the template to compare target datasets generated from 
recordings made during each treatment day. Distinct syllable types were identified by 
clustering within a plot of an acoustic feature measure on the y-axis and syllable duration 
on the x-axis. One or two acoustic features were used as necessary to distinguish two-
dimensional syllable clusters. These parameters were optimized for each subject. Once 
syllable clusters were identified, SongSeq calculated probabilities of each possible pair 
of syllable types being produced on that recording day. The highest probability transition 
on the baseline day for each syllable type was designated the “typical transition” for that 
syllable pair. The percentage of typical transitions for each treatment day was then 




2.2.8 Vocal production measures 
To measure vocal production, recordings in WAV format were sorted using the 
method described by Wu et al., 2008 to ensure each documented an incidence of singing 
(not only calls/extraneous sounds). Sorted song files were counted and each was 
considered a bout of singing. The daily average number of song bouts during baseline 
days 1–3 were determined and used to calculate percent baseline song bouts from counts 
taken for each pre- and post-microlesion day.  
2.2.9 Statistical analyses 
Potential lesion extent differences across drug treatment groups were assessed 
using 1-way ANOVA. Lesion extent data are expressed as means +/- SEM. To assess 
differences in phonology, syllable sequencing and vocal production over experiment day, 
across treatment groups and microlesion conditions, we used a mixed-effects modeling 
approach with SPSS software (version 22). This method controls for lack of independence 
of repeated measures derived from single animals (e.g. 20 daily measures from each 
animal, Aarts et al., 2014).  
For mixed model analysis of phonology, syntax and production data, individual 
animals were treated as random subjects and lesion group (microlesion, sham-
microlesion, no-microlesion), drug treatment (vehicle, 1, 10, 100 mg/kg CBD, 0.1 mg/kg 
WAY + 1 mg/kg CBD) and experiment day were used as fixed factors. For all mixed model 
analyses, the variance components covariance structure and the maximum likelihood 




Improvements to simpler models gained by variable additions were determined through 
likelihood ratio (LR) tests of differences between -2*log likelihood values from the fit of 
each model to vocal behavior data.  
For each assessment, models included animal ID as a random factor to control for 
repeated measures, and experimental day was added as the first fixed explanatory 
variable. As subsets of animals were assigned to drug treatment groups (vehicle, 1, 10 
and 100 mg/kg CBD and 0.1 mg/kg WAY + 10 mg/kg CBD) and these groups were further 
divided into lesion condition (microlesion, sham- and no-microlesion), microlesion group 
nested within CBD dosage were added as fixed factors. Differences between vehicle 
control and CBD-treated groups were determined from pairwise comparisons using the 
Bonferroni post-hoc correction. Probabilities less than 0.05 were considered significant. 
Mixed model statistics reported below are mean differences, with bracketed 95% 
confidence intervals. Figures three, four and five summarize means +/- SEM. 
2.3 Results 
2.3.1 Microlesion extent 
The overall mean lesion extent was 8.6% +/- 0.7, (see Figure 2A). No significant 
differences were observed across groups following one-way ANOVA (F[4, 24] = 0.38, 
p=0.82). Notably, microlesion effects on syllable acoustics appear restricted to those that 
are part of learned vocalizations – unlearned, instinctive, call-type syllables appear 




2.3.2 Mixed model fit to phonology, sequence and vocal production data 
The mixed model fit of vocal behavior measures to explanatory variables was 
optimized as described above. Adding experimental day as a fixed factor to models with 
animal ID as a random factor significantly improved their fit to: (1) KL distance measures 
of phonology (note that these data were normalized by log transformation prior to analysis 
and that Figure 2.3 depicts untransformed means +/- SEM, likelihood ratio [LR] = 927 – 
353 = 2 574, 1 d.f., p < 0.001); (2) percent typical transition data (LR = 932 – 431 = 2 
501, 1 d.f., p < 0.001) and; (3) vocal production data (LR = 11919 - 11250 = 2 670, 1 
d.f., p < 0.001). These results demonstrated significant differences across experimental 
day for each measure. Next, microlesion condition group (microlesion, sham-microlesion 
and no-microlesion) nested within treatment group (vehicle, 1, 10, 100 mg/kg CBD, and 
for the 0.1 mg/kg WAY + 10 mg/kg CBD microlesion group) were added as fixed factors 
to models. These additions further improved model fit to: KL distance data (LR = 353 – 
5.6 = 2 347.4, 2 d.f., p < 0.001); percent typical transitions (LR = 431 – 201 = 2 230, 2 
d.f., p < 0.001) and vocal production (LR = 11250 – 11076 = 2 174, 2 d.f., p < 0.001). 
This demonstrated significant differences across lesion condition and drug treatment 
groups for each vocal behavioral measure.  
2.3.3 CBD improved phonology 
KL distance measure differences across microlesion condition groups at each CBD 
dosage are summarized in Figure 2.3. Comparing microlesion group animals (Figure 3A) 




reported, HVC microlesions reversibly disrupted phonology for about seven days 
(Thompson et al., 2007; Thompson and Johnson, 2007). 
Consistent with a protective effect of CBD, animals with microlesion treated with 
10 or 100 mg/kg CBD showed significantly lower KL distance measures on multiple 
recovery days than vehicle controls (Figure 3A). Compared to VEH controls the 10 mg/kg 
CBD dosage significantly reduced KL distances on all recovery days (by: 0.74 [0.11-1.37], 
p=0.011; 1.20 [0.61-1.79], p<0.001; 0.95 [0.43-1.47], p<0.001; 0.82 [0.35-1.28], p<0.001; 
0.71 [0.25-1.17], p<0.001; 0.64 [0.17-1.12], p=0.002; 0.78 [0.33-1.24], p<0.001; 0.77 
[0.30-1.24], p<0.001; 0.58 [0.10-1.06], p=0.007 and; 0.70 [0.21-1.20] p=0.001, 
respectively). The 100 mg/kg CBD dosage reduced phonology disruptions on recovery 
days 1-5 and 7-10 (by 0.85 [0.24-1.46], p=0.001; 0.87 [0.30-1.43], p<0.001; 0.64 [0.15-
1.13], p=0.003; 0.58 [0.14-1.02], p=0.003; 0.48 [0.04-0.91], p=0.024; 0.47 [0.034-0.90], 
p=0.026; 0.51 [0.07-0.95], p=0.013; 0.048 [0.02-0.93], p=0.032 and; 0.51 [0.04-0.99] 
p=0.024, respectively). Treatment with the 5-HT1A antagonist WAY (0.1 mg/kg) prior to 
administration of 10 mg/kg CBD resulted in significantly lowering KL distances on 
recovery days 2-5 and 7 (by 0.95 [0.39-1.51], p<0.001; 0.70 [0.21-1.20], p=0.001; 0.55 
[0.11-0.99] p=0.006; 0.49 [0.049-0.93], p=0.019 and; 0.51 [0.07-0.94], p=0.011, 
respectively), five fewer days than 10 mg/kg CBD alone. 
2.3.4 CBD modestly improved syntax in microlesioned animals 
Microlesion effects to disrupt syntax as measured by percent typical syllable 
transitions are evident from comparisons of Figure 4A to surgery control groups in Figure 




similar across treatment groups (Figure 4A). Also contrasting with phonology results was 
a modest treatment effect observed in sham-lesioned 10 mg/kg CBD-treated animals that 
had significantly lower syntax on recovery day 8 (-22.4% [-0.2 to -45.1], p=0.046, Fig 4B). 
This suggests an additive effect with the craniotomy procedure that is perhaps consistent 
with promotion of hypolocomotor efficacy (Britch et al. 2017).  
Although the magnitude of syntax disruptions one day post-microlesion were 
similar across treatment groups, CBD-treated animals appeared to recover more rapidly 
than vehicle controls. This trend was significant in the case of 10 and 100 mg/kg CBD-
treated groups. The 10 mg/kg CBD-treated group produced significantly higher 
percentages of typical syllable transitions than vehicle controls on recovery days 4 and 6 
(by: 22.5% [1.5-44.9], p=0.049 and; 24.3% [3.0-45.6], p=0.014, respectively). The 100 
mg/kg CBD improved syntax recovery on day 4 (by: 22.8% [1.5-44.2], p=0.028).  
2.3.5 Complex CBD effects on vocal production 
Consistent with earlier reports (Thompson et al. 2007) HVC microlesions 
effectively reduced vocal output of all treatment groups to a fraction of baseline levels 
(Figure 2.5A). Only 10 mg/kg CBD showed evidence of improved recovery of singing 
behavior relative to vehicle controls on recovery day 2 (by 68.6% [10.0-127.1], p=0.011). 
An interesting pre-microlesion trend toward a reduction in vocal activity was observed in 
the group treated with both WAY and CBD, which suggests a role for 5-HT1A signaling in 
vocal motor processes, although this apparent difference was not statistically significant. 
Following microlesion procedures both 1 mg/kg CBD and WAY + CBD treatment groups 




group this was on recovery days 5 (by 52.2 [1.7-102.8], p=0.038) and 9 (by 59.8 [1.6-
117.9], p=0.039). For the WAY + CBD group this was on recovery day 9 (by 60.2 [2.04-
118.3], p=0.037). Differential efficacy of 1 and 10 mg/kg CBD on vocal production 
suggests a complex, hormetic dose-response relationship that has been well-
documented for CBD in other systems (e.g. Gallily et al. 2015; Antonio W Zuardi et al. 
2017). Note that such “inverted U-shaped” responsiveness is also characteristic of lesion 
studies (Calabrese,2008). The sham procedure clearly reduced vocal output in controls 
and animals treated with 100 mg/kg CBD (Figure 5B). Both 1 and 10 mg/kg appeared to 
mitigate this sham effect with 1 mg/kg producing significant improvement relative to 
vehicle on the first recovery day (by 60.20% [5.35-115.00], p=0.023). 
2.4 Discussion 
2.4.1 CBD effects on microlesion recovery 
Two of the three vocal behavior measures employed in this study (phonology and 
syntax) clearly indicate CBD is effective in mitigating effects of HVC microlesions (Figures 
3A and 4A). The 1 and 10 mg/kg dosages appeared to modestly improve recovery of 
vocal output (Figure 5A). Improved recovery appears to involve both preventing effects 
following HVC damage (secondary to tissue damage itself), and to hastening the process.  
Interaction with processes secondary to tissue damage is indicated by the lack of 
differences across treatment groups in the amount of HVC destroyed (by an average of 
8.6% across all groups, Figure 2A). Thus, the effect of CBD was not to reduce the size of 




from and secondary to tissue damage itself. Given similarities noted in studies employing 
ischemic stroke models (Ceprián et al., 2017; Mori et al., 2017) these secondary 
processes may include reductions of excitotoxicity, neuroinflammation, metabolic 
derangement, gliosis and/or protection of astrocyte function. Whatever the secondary 
processes are (and these will be important to address in future studies), their mitigation 
improves ability of adult songbirds to relearn to produce memorized vocal patterns. 
Elucidation of neurophysiological effects of CBD in this model may prove relevant to its 
clinical efficacy and potential to improve cognition in children with seizure disorders. 
That relearning is required is evident from the fact recovery of vocalizations 
depends upon ability of birds to hear themselves sing. Deafened animals don't receive 
the auditory feedback necessary for sensorimotor relearning and do not recover high-
quality song (Thompson et al., 2007). It may also be important that the microlesion effect 
is restricted to motif syllables and does not appear to impair instinctive calls (Figure 2C 
and D). This suggests that CBD prevents degradation of a learned behavior, consistent 
with improved memory in dementia models (Karl et al., 2017). Prior work has 
demonstrated lesions of lMAN (the output nucleus of the learning-essential anterior 
forebrain pathway [AFP, Bottjer et al., 1984]), prior to HVC microlesions, prevent impaired 
vocal behavior (Thompson and Johnson, 2007). This demonstrates that effects of HVC 
microlesions cannot be attributable to damage of HVC itself, but must follow from some 
related disruption involving lMAN. Therefore, brain regions and circuits outside of the 
motor-related microlesion target HVC must be involved in the efficacy of CBD to mitigate 




Brain regions with established relevance to the HVC microlesion model, and 
interconnections between them are summarized in Figure 1A. The different pathways and 
nuclei within these separate vocal control and production circuits have distinct effects on 
vocalizations. Activity within HVC is most clearly associated with syllable timing 
(Hahnloser et al., 2002) and those within lMAN and RA appear more important to 
phonology (Kao et al., 2005; Sober et al., 2008; Vu et al., 1994). As song is modulated 
by midbrain dopaminergic neuronal activity (Hara et al., 2007) vocal production also 
involves motivation systems important for incentive learning and reward. Thus, effects of 
CBD upon vocal production, syntax and phonology provide insight to potential brain 
nuclei, circuits and systems mechanistically involved.  
2.4.2 CBD effects on vocal production 
Relative to phonology and syntax measures, effects to improve vocal production 
were more modest and variable (Figure 5A). Variability may involve an “inverted U-
shaped” hormetic dose-response relationship for this effect that has been described for 
CBD in other systems (Gallily et al., 2015; Zuardi et al., 2017). Modest efficacy in this 
motor-dependent measure may make sense in the context of established ability of CBD 
to reduce motor activity in rats (Espejo-Porras et al., 2013) although this rodent effect is 
thought attributable to striatal circuits. The songbird vocal motor system (Figure 1A) is 
likely more relevant to effects of CBD on vocal production observed here. This pathway 





2.4.3 CBD effects on syntax 
CBD accelerated recovery of typical syllable transitions as indicated by recovery 
in CBD-, but not vehicle-treated microlesioned animals, to pre-microlesion levels by the 
end of experiments (Figure 4A). Both 10 and 100 mg/kg CBD treatments were effective 
in improving this measure of syntax. 
A potentially-important feature of syntax responses includes a trend in 1 and 10 
mg/kg CBD-treated animals to exhibit a biphasic syntax recovery, with an initial rapid 
response over five to six days followed by a flat response or even regression in the 10 
mg/kg group (Figure 4A). Regression in the 10 mg/kg group late in the recovery period is 
also suggested in sham-microlesioned animals, where typical transitions were 
significantly reduced relative to control on day 8 (Figure 4B). In addition to adding to 
evidence of complex CBD dose-response relationships, possible biphasic recovery 
suggests involvement of temporally-distinct physiological processes. Doses of 1 and 10 
mg/kg CBD appear more effective in mitigating the earlier of these processes. The higher 
100 mg/kg CBD dose demonstrated less of a biphasic restoration of typical syllable 
transitions, a result suggesting potentially distinct efficacy to improve syntax. 
2.4.4 CBD effects on phonology 
The most conspicuous CBD effect observed was reduction of the magnitude of KL 
distance measures immediately following microlesions. All CBD treatments significantly 
reduced phonological disruptions (Figure 3A) but in the case of both 10 and 100 mg/kg 




that our microlesion target was HVC, a motor region most clearly associated with syntax-
relevant syllable timing. Phonology appears more dependent upon the AFP and its lMAN 
output to RA (Figure 1A, Kao et al., 2005; Vu et al., 1994). Given that ability of 
microlesions to disrupt vocalizations depends upon intact lMAN (as discussed above, and 
see Thompson et al., 2007) a simple potential mechanism for observed ability of CBD to 
nearly eliminate phonology disruptions includes interference with lMAN activity. CBD 
inhibition of lMAN output is a hypothesis to be tested, and could follow from effects within 
any of the nuclei that comprise the AFP (Area X, DLM, lMAN, Figure 1A) or via action as 
far upstream as the HVC projection to Area X.  
Finally, the fact that KL distances in 10 and 100 mg/kg CBD-treated animals never 
approached vehicle control levels, even immediately following microlesions (Figure 3A), 
suggests the six-day pretreatment period was an important factor. This has implications 
for potential therapeutic use of CBD in cases of CNS trauma that will depend upon after-
incident administration. Thus, it will be important in future studies to establish relative 
contributions of pre- vs. post-microlesion CBD treatments. 
2.4.5 Potential mechanism of action 
Given evidence of CBD agonism of 5-HT1A receptors (Resstel et al., 2009; Russo 
et al., 2005), we used an antagonist, WAY, as a first step toward identifying potential 
mechanisms. Originally described as a selective antagonist (Fletcher et al., 1995), it is 
now clear WAY also interacts with D4 dopamine, alpha1A-adrenergic and 5-HT2B receptors 
with about 10X lower affinity than for 5-HT1A (16.4, 19.9, 24 nM, respectively vs. 2.2 nM, 




a very modest dosage of 0.1 mg/kg (note this dosage is >10X lower than required for rat 
discrimination [1.4 mg/kg,  Marona-Lewicka and Nichols, 2009]). WAY pretreatment prior 
to 10 mg/kg CBD reduced the number of days with improved phonology and syntax by 
five and two, respectively (Figsure 3A and 4A). Partial reversal of CBD efficacy suggests 
5-HT1A involvement, but additional controls are needed for clear determination. Given the 
numerous macromolecular targets of CBD (reviewed by Ibeas Bih et al., 2015; 
Soderstrom et al., 2017) it is possible, if not likely, that multiple targets are relevant to the 
efficacy observed. 
2.5  Conclusions 
We have demonstrated ability of CBD to improve recovery following damage to a 
pre-vocal motor brain region. This improved recovery included both reduction of the 
magnitude of lesion effects, and less time required for restoration of vocal patterns. All 
CBD dosages showed efficacy, with 10 mg/kg appearing superior in phonology and on 
measures of syntax. Taken together, our results suggest CBD holds therapeutic promise 
for treatment of speech- and/or language-related disorders. This microlesion model will 
allow identification of mechanisms responsible for CBD-improved vocal behavior, and 
provide insight to signaling systems that control vocal learning and production. In addition 
to demonstrating CBD efficacy, the work has established a pre-clinical animal model 





Figure 2.1: Experimental approach.  
A, camera lucida-type drawing illustrating brain regions and circuits relevant to CBD 
effects on vocal behavior. Black shading corresponds to song regions within the section 
traced (HVC, RA, lMAN, Area X) and grey shading indicates striatum. Light grey areas 
with dashed borders indicate relevant regions not present in the traced section. Rose 
arrows indicate connections of the anterior forebrain pathway (AFP), a cortico-basal 
ganglia-thalamic loop critical for sensorimotor vocal learning (reviewed by Perkel, 2004). 
Note output from lMAN to the vocal motor output region, RA (Bottjer et al., 1989). Blue-
green indicates vocal motor pathways. Note output from pre-motor HVC to the basal 
ganglia region, Area X. Gold arrows indicate auditory input to the motor system (Kelley 
and Nottebohm, 1979; Vates et al., 1996) and from the ventral portion of the intermediate 
arcopallium (AIV) to dopaminergic neurons within substantia nigra (SN)/ventral tegmental 
area (VTA, Mandelblat-Cerf et al., 2014). Note SN/VTA dopaminergic projections to spiny 
interneurons within Area X of striatum (Ding and Perkel, 2002). Rostral is right, dorsal is 
up and bar = 1 mm. Abbreviations: DLM (nucleus dorsolateralis anterior, pars medialis), 
HVC (proper name), lMAN (lateral magnocellular nucleus of the anterior nidopallium), CM 
(caudal mesopallium), RA (robust nucleus of the arcopallium). B, experimental time-line 











Figure 2.2: Effects of microlesions. 
 A, lesion extent did not differ across drug treatment groups (mean=8.6 +/- 0.7%, one-
way ANOVA (F[4, 24]=0.38, p=0.82). B, illustration of method used to measure lesion 
extent of Nissl-stained parasagittal sections (dorsal up, rostral right, 12.5X inset bar = 1 
mm, 40X bar = 300 m). All HVC-containing sections were imaged. ImagePro software 
was used to trace both HVC and infarcts, if present. Lesion extent = infarct area/HVC 
area x 100%. C, audiospectrogram examples of song illustrate behavioral effects of 
microlesions in a vehicle control animal. On Baseline Day 1 motifs (indicated by bars) are 
produced with consistent syntax, and syllables (sound separated by silence) show good 
phonetic structure.  Syntax and phonology of motif syllables are disrupted on Post-
Microlesion Day 1, although phonetics of instinctive, unlearned calls appear unaffected. 
Phonology has improved by Post-Microlesion Day 3 while syntax remains impaired. By 
the final day of the experiment (Post-Microlesion Day 10) motif syntax and phonology 
have recovered. D, sonogram examples of microlesion effects on song in an animal 
treated with 10 mg/kg CBD shows good syntax and phonology on Baseline Day 3. Effects 
of the microlesion procedure on syntax and phonology are apparent on Post-Microlesion 
Day 1, although relative to the vehicle-treated control, effects are modest. Phonology and 
syntax structure have improved by Post-Microlesion Day 3. By Post-Microlesion Day 10, 

















Figure 2.3 :KL distance measures of phonology by surgery and drug treatment 
group.  
A, in microlesioned animals, KL distances are clearly increased in VEH and 1 mg/kg CBD-
treated animals indicating significant disruption of phonology relative to baseline. Asterisk 
color indicates significant differences from VEH (mixed-model ANOVA with Bonferroni 
correction for post-hoc comparisons). Both 10 and 100 mg/kg CBD treatments 
significantly reduced KL distance measures relative to VEH immediately post-microlesion 
suggesting protective effects produced by the six-day pre-treatment period. 10 mg/kg 
CBD was still effective following 0.1 mg/kg of the 5-HT1A-selective antagonist WAY, 
although on fewer days than 10 mg/kg alone suggesting possible involvement of this 
receptor in the mechanism responsible for CBD efficacy. Panel B shows phonology 
trajectories from representative VEH- and 10 mg/kg CBD-treated animals (see Fig 2 C 
and D for sonogram examples). Panels C and D demonstrate little phonological change 
in sham- and no-microlesion control groups across treatment groups. Hatched line 










Figure 2.4: Syntax quality measured through percent typical syllable transitions 
by surgery and drug treatment group.  
A, in microlesioned animals, typical transitions were significantly reduced in all treatment 
groups to a similar degree immediately post surgery. In 10 and 100 mg/kg CBD treatment 
groups syntax recovery was improved relative to VEH as indicated by significantly higher 
typical transitions on at least one recovery day. Asterisk color indicates significant 
treatment group differences determined by mixed-models post-hoc tests with the 
Bonferroni correction for multiple comparisons. Similar to effects on phonology, 0.1 mg/kg 
WAY + 10 mg/kg CBD resulted in two fewer days with significantly better syntax than 
CBD alone.  Both 1 and 10 mg/kg CBD appeared to improve syntax recovery at a higher 
rate early in the recovery period, followed by a flattened response later. 100 mg/kg 
showed consistent efficacy over recovery days. B, the sham procedure had little effect on 
syntax measures. Significantly lower syntax in 10 mg/kg CBD-treated sham controls 
relative to VEH late in the recovery period is similar to the leveled-off response observed 
in microlesioned animals, and may indicate an interaction with the craniotomy procedure. 










Figure 2.5: Vocal output measured by percent baseline song bout production. 
 A, microlesions almost eliminated vocal production across all treatment groups. 10 and 
100 mg/kg CBD appeared to improve recovery relative to other groups on recovery days 
two and five, respectively (mixed-models post-hoc tests with the Bonferroni correction for 
multiple comparisons). Both 1 mg/kg CBD and CBD+WAY resulted in significantly lower 
vocal production on recovery day 10, suggesting a differential, hormetic CBD dose-
response and potential 5-HT1a receptor activity to promote vocal behavior. B, the sham 
procedure also appeared to reduce output in VEH and 100 mg/kg-treated animals. 1 
mg/kg CBD significantly improved vocal output on recovery day 1. C, the no-microlesion 
procedure did not produce a significant effect on vocal output in any of the treatment 








CHAPTER 3: CANNABIDIOL IMPROVES VOCAL DEVELOPMENT FOLLOWING 
DAMAGE TO lMAN, A REGION IMPORTANT FOR SENSORIMOTOR VOCAL 
LEARNING 
3.1 Introduction 
Cannabidiol (CBD) is one of many molecules derived from Cannabis that is 
structurally-related to the principal eurphorigenic cannabinoid, 9-tetrahydrocannabinol 
(THC). Although not associated with euphoria like THC, CBD is clearly psychoactive and 
is known to interact with many cellular macromolecules expressed within CNS (reviewed 
by Ibeas Bih et al., 2015; Soderstrom et al., 2017).  
Because of a range of efficacies and array of cellular targets CBD holds promise 
for the treatment of many disorders, notably including seizures, muscle spasms, anxiety, 
and autism. Recently, there have been several important clinical trials done to 
demonstrate CBD is effective in reducing spasms, muscle stiffness, and pain associated 
with multiple sclerosis (Holdcroft et al. 2006). Moreover, other clinical trials have 
demonstrated CBD is an effective therapy for treatment children suffering from intractable 
seizures such as Dravet syndrome and Lennox-Gastaut syndrome. Results showed a 
reduced seizure frequency by approximately 43% for Dravet and Lennox-Gastaut 
syndrome patients (Thiele et al. 2018; Trial of CBD for Drug-Resistant Seizures in the 
Dravet Syndrome 2017), and it produces positive effects with promising results (Tzadok 
et al. 2016). Among these results is suggestion that CBD may improve vocal learning. 
In addition to childhood seizure disorders, several other vocal learning and 




(Godoy et al. 2014; Mayo clinic staff 2015; Özbal Koç et al. 2016), trauma, and autism. In 
the US, there are about 7.5 million people that have difficulty using their voices (National 
Institue on Deafness and Other Communication Disorders (NIDCD) 2016). Globally in 
2013 (Global Burden of Disease Study 2013 Collaborators 2015), approximately 21.7 
million people had been diagnosed with autism spectrum disorder. In the United States, 
about one in 68 children were diagnosed with autism in 2014 (Autism and Developmental 
Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and 
Centers for Disease Control and Prevention 2012; Blumberg et al. 2013). One of the 
characteristics that is associated with autism is a vocal learning defect (Condro and White 
2014; Panaitof 2012) and about 50% or more of these patients displayed early abnormal 
acoustics patterns (Fusaroli et al. 2016; Paul et al. 2005; Rogers et al. 2006; Shriberg et 
al. 2001). 
We have developed a unique songbird preclinical animal model to investigate drug 
effects to improve learning-dependent recovery following damage to a vocal cortical-like 
brain region. In the model, CBD was found to improve vocal recovery following electrolytic 
ablation of about 10% of pre-vocal motor HVC (used as a proper name). This partial 
damage is recovered from in about seven days in untreated animals. CBD administered 
once daily via IM injection of 10 mg/kg significantly reduced time to recover both vocal 
phonology and syntax. In the case of phonology, the magnitude of lesion-related deficits 
were also reduced. This experiment, done in adult animals, made us consider if similar 
efficacy to promote vocal learning would be observed during the songbirds’ critical period 
for vocal development during which song patterns are memorized and practiced. Such 




language-related disorders, including those associated with autism.  
Because of the need to find a drug effective for treating disorders like autism that 
is related to vocal learning, this project investigated the effect of CBD to improve vocal 
learning during the time that it is naturally acquired. 
Zebra finch is a good model for testing this hypothesis as, in a manner similar to 
humans, male zebra finches learn how to produce a form of vocal communication (Scharff 
and Nottebohm 1991).  In both humans and zebra finches, youngsters listen to and 
memorize vocal patterns produced by tutors, this called sensory learning stage. Then in 
sensorimotor learning stage, learners start to practice producing vocalizations, refining 
them through auditory feedback until a good copy is produced (Doupe and Kuhl 1999; 
Brainard and Doupe 2002). Convergent pathways control vocal learning and production 
in both the zebra finch and humans (Nottebohm 2005; Simmonds 2015). These pathways 
include: one in rostral telencephalon for vocal learning termed the “anterior forebrain 
pathway” (AFP) and a caudal vocal motor pathway (Simmonds 2015). The vocal learning 
pathway in zebra finches includes lMAN, Area X , and DLM  whereas the  vocal motor 
pathway includes  HVC and RA (Nottebohm 2005; Simmonds 2015) (Figure1.3). The 
vocal learning pathway in humans involves these areas: cortex, striatum, and thalamus 
(Simmonds 2015).  The vocal motor pathway involves these areas: premotor cortex and 
motor cortex (Simmonds 2015)  (Figure 1.3) . For these reasons, we used zebra finch to 
test the hypotheses of this project. 





Unless otherwise indicated all materials and reagents were purchased from Sigma 
or Fisher. CBD was provided by GW Pharmaceuticals, Cambridge, UK. Two CBD 
dosages were employed: 0 (vehicle control), 10 mg/kg. CBD suspended in vehicle from 
10 mM ethanol stocks. Vehicle consisted of a suspension of 2:1:17 Ethanol:Alkamuls EL-
620 (Rhodia, Cranberry, NJ):phosphate-buffered saline. Equithesin was prepared from 
reagents (40 % propylene glycol, 10 % ETOH, 5 % chloral hydrate, 1 % pentobarbital).  
3.2.2 Animals and audio recording environment  
Male zebra finches were raised in our breeding aviary. At about day 25 of age, 
they were transferred to tutor cage until day 45 of age. Then, they were individually 
housed in small cages (29 x 22 x 42 cm) with ad libitum food and water. There were four 
recording periods: at about 45, 60,75, 90 and 94 day of their age and in these times, 
animals were placed in recording chambers. Birds were visually isolated during the 
vocalization recording and they were not female-directed. Each recording chamber was 
fitted with a microphone and an individual light. Sound Analysis Pro 2011 software   
(Tchernichovski et al. 2000) was used to record vocalizations and store them in Waveform 
Audio File Format. Animals were maintained at 78° F on a 12/12 light/dark cycle. All 
animal procedures were approved by the East Carolina University Animal Care and Use 
Committee. 
Intended group numbers were n = 6 animals per treatment and surgery condition. 




overall mean of 5.93 (+/- 0.843) motif syllables (range = 4-8 syllables) and motif 
complexity did not differ significantly across the groups (2-way ANOVA, F(8,45)=0.493, 
p=0.855) (see Table 2). 
3.2.3 Experimental design 
To test the effect of CBD on vocal learning we used juvenile male birds in the 
auditory learning stage. Because these birds do not develop secondary sex 
characteristics before the age they were needed for these developmental experiments, 
PCR was used to determine their sex following the procedure previously described 
(Thompson et al. 2007). Adult males tutored these juvenile birds. At age 35 days, which 
is approximately the end of the auditory learning stage and beginning of the sensorimotor 
learning stage overlap; the unilateral lMAN lesions were done from late-morning to early-
afternoon. Three groups of developmental birds were treated with CBD and VEH once 
daily treatments were delivered in the morning in a volume of 50 ul IM to pectoralis. These 
three groups are: First group received VEH from day 30 to day 90; Second group received 
10 mg/kg CBD for 10 days from day 30 to day 40, and VEH from day 41 to day 90; Third 
group received 10 mg/kg CBD from day 30 to day 90. CBD injections started 5 days 
before surgery to reach to a presumed steady state level before surgery.  Also, no-surgery 
and sham controls were evaluated with all three dosages. To determine if the lesion 
produces a confounding effect, sham groups were required. Also, no surgery groups are 
important to confirm the anesthetic agent (isoflurane) that is used during surgery does not 
produce a confounding effect. The number of birds used were 54 males, 6 birds for each 




used for an entirely objective analysis. Finally, to confirm the location of lesions and 
measure their size, the birds were euthanized and the brains were fixed. Sham group 
birds received all these processes except for the destroying of IMAN.  Whereas no 
surgery animals did not undergo surgeries. The treatment plan employed is summarized 
in Figure 3.1 B and C. 
3.2.4 Microlesion surgeries 
For animals in the lesion group, each was subjected to unilateral craniotomy over 
lMAN following the procedure previously described (Thompson et al. 2007) except that 
animals were administered the anti-inflammatory drug meloxicam (1 mg/kg) 30 min prior 
to procedures and were anesthetized by isoflurane inhalation. For these procedures, birds 
were deeply anesthetized by face mask (4% isoflurane in O2 at 1 L/min) and secured in 
a stereotaxic instrument. Once secured, anesthesia was maintained with 2.5% isoflurane 
in O2 at 1 L/min by mouth through a small diameter tube passed through a hole drilled 
through the bite bar. The skull was exposed by cutting the scalp down the midline and 
retracting the skin using forceps. To determine lMAN location, the bifurcation at the 
midsagittal sinus was used as stereotaxic zero. A small craniotomy was placed over the 
location of lMAN in right hemisphere. To produce lesion that destroy approximately 100 
% of right lMAN, we placed an electrode (Teflon insulated tungsten; 200 um diameter; A-
M Systems, Everett, WA) in one location. At 3.8 mm anterior from stereotaxic zero, 
mirrored laterally from the midline 1.8 mm, penetration was to a depth of 2.7 mm, and for 
3.5 min the current was set at 100 uA. Wounds were closed with interrupted sutures and 




cages. Animals in the sham-lesion group were subjected to all of the steps described 
above for the lesion group except that no current was passed through the electrodes. 
Therefore, sham birds were exposed to meloxicam analgesia, anesthesia with isoflurane, 
craniotomies, electrode insertion and interrupted sutures. Animals in the no-lesion control 
group were transported to the operating room with lesion and sham-group animals, but 
were not subjected to any other manipulation. Thus, the no-lesion group served to control 
for potential effects of the craniotomy procedure itself, including analgesic and anesthetic 
drug treatments. 
3.2.5 Lesion extent 
Following recording, animals were overdosed with Equithesin. Brains were 
removed and post-fixed in paraformaldehyde at 4o C overnight. Post-fixed brains were 
blocked parasagittally down the midline and right hemisphere sectioned through lMAN at 
40 microns. Sections were mounted on gelatin-subbed slides and Nissl stained. Sections 
containing lMAN lesion were imaged at 40 X. The extent of lesion damage was calculated 
by tracing borders of lMAN and infarcts, if present, using ImagePro Plus software. The 
total area of lMAN and the infarct were summed, and percent lesion extent expressed as 
infarct area divided by lMAN area x 100 % (Figure 3.2).  
3.2.6 Vocal production measured by measuring duration of singing per hour 
To measure vocal production, recordings in wave form audio file format were 
sorted and duration for each syllable were calculated using SAP2011. To ensure that all 




version 2 was used to assign motive and non-motive syllables. Then, MySQL Workbench 
6.3 CE was used to create a new syllables table for motive syllables only. After that the 
syllables durations were summed and divided by hours of recording to find out duration 
of singing per hour. Then to measure the variability in vocal production, the percentage 
of duration of singing for each animal was divided by the average of duration of singing 
for VEH-no lesion animals. 
3.2.7 KL distance measures of phonology 
Animals were recorded at days 45, 60, 75, 90, and 94 of age using Sound Analysis 
Recorder software (Tchernichovski et al. 2000) . Recordings in Waveform Audio File 
Format were input to Sound Analysis Pro 2011 (Tchernichovski et al. 2000) to segment 
song files into their separate syllable components. Segmentation into syllables using SAP 
was accomplished by thresholding based upon amplitude, entropy, syllable and syllable 
gap durations. Values of these acoustic features used for thresholding were optimized for 
individual animals. After this optimization, further analysis of segmented syllables was 
accomplished entirely objectively. SAP characterizes individual syllables by their spectral 
structure through measures of acoustic features (e.g. syllable duration, mean amplitude, 
mean pitch, mean FM, mean AM2, mean entropy, mean goodness of pitch, mean mean 
frequency, pitch variance, FM variance, entropy variance, goodness of pitch variance, 
mean frequency variance, AM variance). SAP saved acoustic feature measures in 
MySQL database tables. We used these MySQL tables to measure phonology for each 
animal via calculation of Kullback-Leibler (KL) distances using methods developed by 




distributions of vocal acoustic features. Greater KL distance measures reflect increased 
phonological divergence across the vocalizations compared. We used acoustic measures 
from VEH-no lesion animals recording as “template” distribution, and recordings from 
each group of treatments as individual “target”. KL distances between template and target 
distributions were calculated using software we developed (KLFromRecordingDays 
available for download as described in Soderstrom and Alalawi 2017).  
3.2.8 Typical syllable transition measures of syntax 
Syntax was measured from the frequency of typical syllable transitions that were 
calculated using SongSeq software according to the method described by Daou et al., 
2012. SongSeq uses data exported from SAP to identify distinct syllables. Day 90 was 
used as the template to compare target datasets generated from recordings made during 
each time point (45, 60, 75 and 90). Distinct syllable types were identified by clustering 
within a plot of an acoustic feature measure on the y-axis and syllable duration on the x-
axis. One or two acoustic features were used as necessary to distinguish two-dimensional 
syllable clusters. These parameters were optimized for each subject. Once syllable 
clusters were identified, SongSeq calculated probabilities of each possible pair of syllable 
types being produced on that recording time point. The percentage of typical transitions 
for each treatment day was then calculated as the number of typical transitions divided 
by total transitions x 100%.  Then to measure the variability in syntax, the percentage of 
typical transition for each animal was divided by the average percent typical transitions 




3.2.9 Statistical analyses 
To assess differences in phonology, syllable sequencing and vocal production over 
experiment day, across treatment groups and microlesion conditions, we used a mixed-
effects modeling approach with SPSS software (version 24). This method controls for lack 
of independence of repeated measures derived from single animals (e.g. four time points 
measures from each animal, Aarts et al., 2014).  
For mixed model analysis of phonology, syntax and production data, individual 
animals were treated as random subjects and lesion group (microlesion, sham-
microlesion, no-microlesion), drug treatment (vehicle, CBD 30-40 and CBD 30-90) and 
time point were used as fixed factors. For all mixed model analyses, the variance 
components covariance structure and the maximum likelihood method were used. Fixed 
explanatory variables were successively added to models. Improvements to simpler 
models gained by variable additions were determined through likelihood ratio (LR) tests 
of differences between -2*log likelihood values from the fit of each model to vocal behavior 
data.  
For each assessment, models included animal ID as a random factor to control for 
repeated measures, and time point was added as the first fixed explanatory variable. As 
subsets of animals were assigned to drug treatment groups (vehicle, CBD 30-40 and CBD 
30-90) and these groups were further divided into lesion condition (microlesion, sham- 
and no-microlesion), microlesion group nested within treatment group were added as 
fixed factors. Differences between vehicle control and CBD-treated groups were 




Probabilities less than 0.05 were considered significant. Figures 3.3, 3.6 and 3.7 
summarize means +/- SEM. 
 
3.3 Results 
3.3.1 CBD treatment for short period improves phonology  
When songs of birds were analyzed by KL distance to see the effect of CBD on 
phonology in lesion groups at four different ages 45, 60, 75, and 90 days, are 
demonstrated in Figures 3.3. Compared to animals that received vehicle treatment from 
day 30 to 90 days (Figure 3.3 A), the animals that received unilateral lMAN lesion treated 
by 10mg/kg CBD from 30 to 40 days of age (called CBD 30-40) have improved KL 
distance variability in adulthood age (age 90, F[2,210] = 5.68, p=0.047). Whereas, CBD 
30-90 treatment did not significantly alter KL distance comparing to VEH at all time points. 
Sonogram examples of CBD effects on song in an animal received unilateral lMAN lesion 
shows in Figure 3.4. In addition, the effect of short period treatment by CBD from day 30 
to 40 was evaluated in different lesion conditions by KL distance, as shown in Figures 3.3 
B. At age 60 and 90 days, CBD 30-40 treatment significantly improved KL distance in 
lesion animals comparing to no lesion, (F[2,210] = 3.06, p = 0.049 and F[2,210] = 5.919, 
p=0.003, respectively). Whereas, CBD 30-40 treatment did not significantly alter KL 
distance in sham animals compared to no lesion at all time points. Sonogram examples 





3.3.2 CBD treatment for short period speeds maturation of singing  
The effect of CBD treatment on syntax quality across lesion groups at four time 
points 45, 60, 75 and 90 days of the animals ages are summarized in Figure 3.6. This 
figure shows ability of CBD treatment for short period to speed maturation of syllable 
transitions in lesion animals. At age 45 days, CBD 30-40 treatment significantly improved 
typical syllable transitions comparing to VEH, F[2,150.81] = 7.148, p = 0.001. Whereas, 
CBD 30-90 treatment did not significantly alter typical syllable transitions comparing to 
VEH at all time points (Figure 3.6 A). Looking at sonograms there appears to be an effect 
of CBD to hasten maturation of syllable transitions. This is made evident by higher typical 
syllable transitions percentage in the CBD 30-40 group at Day 45 comparing to VEH and 
CBD 30-90 (Figure 3.4). In addition, the effect of the short period treatment with CBD 
from day 30 to 40 was evaluated in different lesion conditions by typical syllable transitions 
percentage as shown in Figures 3.6 B. At age 45 and 60 days, CBD 30-40 treatment 
significantly improved typical syllable transitions in lesion animals comparing to no lesion, 
F[2,150.81] = 7.71, p = 0.001. Whereas, CBD 30-40 treatment did not significantly alter 
typical syllable transitions percentage in sham animals compared to no lesion at all time 
points. In Figure 3.5 sonogram examples of CBD effects on song in an animal received 
either unilateral lMAN lesion, sham or no lesion surgery, shows high typical transitions for 
animals that received unilateral lMAN lesion and treated by CBD 30-40 at age 45 and 60 
days compared to VEH and CBD 30-90 and this suggests that CBD has an effect to 




3.3.3 CBD treatment does not affect vocal output in IMAN lesioned animals 
Figure 3.7 shows the effect of CBD on vocal output of lesion animals. CBD does 
not significantly alter amount of singing per hour in both CBD 30-40 and CBD 30-90 
comparing to VEH group (Figure 3.7 A) F[2,148.74] = 0.523, p = 0.6. In like manner CBD 
30-40 does not significantly alter amount of singing per hour in all lesion conditions 
compared to no lesion group, shown in Figure 3.7 B, F[2,148.74] = 0.27, p = 0.764. 
3.4 Discussion 
3.4.1 CBD effects on syntax 
CBD treatment for a short period (from day 30 to day 40 of animals ages) appears 
to have accelerated maturation of singing in animals that received unilateral lMAN lesion 
in terms of syntax compared to lesioned animals that received VEH (Figure 3.6 A) and to 
no lesioned animals that received CBD for 10 days (30 to 40 day of their ages) (Figure 
3.6 B). Although all animals in adulthood (90 days) reached to approximately the same 
level of typical transitions (a measure of syntax), CBD 30-40 animals had significant 
higher typical transition at age 40 and 60 days. This effect of short period treatment of 
CBD likely involves processes distinct from and secondary to tissue damage itself not 
associated with “rewiring” circuits that control learned vocal behavior. Given similarities 
noted in studies employing ischemic stroke models (Ceprián et al. 2017; Mori et al. 2016), 
these secondary processes may include reductions of excitotoxicity, neuroinflammation, 
metabolic derangement, gliosis and/or protection of astrocyte function. Whatever the 
secondary processes are, these will be important to address in future studies. Moreover, 




to our findings in first project (Figure 2.4 A), CBD has biphasic effects and this biphasic 
effect suggests involvement of temporally-distinct physiological processes. Moreover, this 
variability between long and short periods of treatment with CBD may involve an “inverted 
U-shaped” hormetic dose-response relationship for this effect that has been described for 
CBD in other systems (Gallily et al., 2015; Zuardi et al., 2017). 
In addition, the findings of Scharff and Nottebohm demonstrated bilateral 
destruction of lMAN prevents vocal learning in zebra finch birds (Scharff and Nottebohm 
1991). Furthermore, based on unpublished personal communication, unilateral lesions of 
lMAN prior to sensorimotor vocal development allows for learning of song, but with some 
deficits when compared with control animals. As mentioned before, our results suggest 
CBD helped to speed maturation of song in terms of syntax in unilateral lMAN lesioned 
animals. This result demonstrates that the effect of CBD to improve or speed maturation 
of syntax cannot be attributable to its effect on lMAN itself only, but must follow from some 
related disruption involving HVC, a motor region most clearly associated with syntax-
relevant syllable timing (Hahnloser, Kozhevnikov, and Fee 2002) or increase activity of 
not lesioned lMAN in the second side of the brain . Therefore, other brain regions and 
circuits must be involved in the efficacy of CBD to speed maturation of singing in 
sensorimotor stage. 
3.4.2 CBD effects on phonology 
CBD treatment for a short period significantly improved KL distance variability in 
adulthood time in animals that received unilateral lMAN lesion in terms of phonology 




animals the effect of CBD 30 to 40 days started early at age 60 days ( Figure 3.3 B). 
According to previous studies the activity within lMAN and RA appear more important to 
phonology (Kao, Doupe, and Brainard 2005; Sober, Wohlgemuth, and Brainard 2008; Vu, 
Mazurek, and Kuo 1994). Therefore, the effect of CBD on phonology suggests that CBD 
plays a role through lMAN, RA or both to produce this effect. 
3.4.3 CBD effects on vocal production 
In addition to using phonology and syntax analysis to assess the effect of CBD to 
improve vocal learning, vocal output analysis was used to examine the effect of CBD on 
motor activity after CNS damage. However, CBD did not produce statistically significant 
effects on vocal learning compared to lesioned animals received VEH (Figure 3.7 A) and 
to No-Lesion group animals received CBD (30 – 40) (Figure 3.7 B). Because CBD does 
not have direct effects on CB1, the dose used in this experiment may be less than the 
effective dose to produce an effect in motor activity through interacting with 5HT1A 
receptors. Espejo-Porras et al used 20 mg/kg to demonstrate the ability of CBD to affect 
motor activity (Espejo-Porras et al. 2013).   
3.5 Conclusions 
We have demonstrated the ability of CBD to improve vocal learning following 
damage to lMAN that plays a major role in vocal learning during the sensorimotor stage. 
Treatment with 10 mg/kg CBD for 10 days was effective at improving vocal learning in 
terms of phonology and on measures of syntax. Therefore, our results suggest CBD holds 




addition to demonstrating CBD efficacy, the work has established a pre-clinical animal 





Table 3.1: Summary of animals used for each group. 
A total of 54 animals were included in the analysis and 52 animals were excluded: 14 animals 
died before end of the experiment, sexing by PCR resulted in 11 erroneous sex assignments, 
























No lesion 7 0 1 0 6 
Sham 8 1 1 0 6 
lesion 19 3 3 7 6 
CBD 30-40 
No lesion 7 0 1 0 6 
Sham 6 0 0 0 6 
lesion 26 6 3 11 6 
CBD 30-90 
No lesion 7 0 1 0 6 
Sham 7 1 0 0 6 





Table 3.2: Similar motif syllable numbers across treatment groups. 
No treatment group sang significantly more- or less complicated song patterns in 













CBD 30-40 6.0 5.3 6.7 
CBD 30-90 5.7 4.9 6.4 
VEH 6.0 5.3 6.7 
Sham 
CBD 30-40 5.8 5.1 6.6 
CBD 30-90 6.3 5.6 7.1 
VEH 6.2 5.5 6.9 
lesion 
CBD 30-40 5.5 4.8 6.2 
CBD 30-90 5.8 5.1 6.6 







Figure 3.1: Experimental approach.  
A, camera lucida-type drawing illustrating brain regions and circuits relevant to CBD 
effects on vocal behavior. Black shading corresponds to song regions within the section 
traced (HVC, RA, lMAN, Area X) and grey shading indicates striatum. Light grey areas 
with dashed borders indicate relevant regions not present in the traced section. Rose 
arrows indicate connections of the anterior forebrain pathway (AFP), a cortico-basal 
ganglia-thalamic loop critical for sensorimotor vocal learning (reviewed by Perkel, 2004). 
Note output from lMAN to the vocal motor output region, RA (Bottjer et al., 1989). Blue-
green indicates vocal motor pathways. Note output from pre-motor HVC to the basal 
ganglia region, Area X. Gold arrows indicate auditory input to the motor system (Kelley 
and Nottebohm, 1979; Vates et al., 1996) and from the ventral portion of the intermediate 
arcopallium (AIV) to dopaminergic neurons within substantia nigra (SN)/ventral tegmental 
area (VTA, Mandelblat-Cerf et al., 2014). Note SN/VTA dopaminergic projections to spiny 
interneurons within Area X of striatum (Ding and Perkel, 2002). Rostral is right, dorsal is 
up and bar = 1 mm. Abbreviations: DLM (nucleus dorsolateralis anterior, pars medialis), 
HVC (proper name), lMAN (lateral magnocellular nucleus of the anterior nidopallium), CM 
(caudal mesopallium), RA (robust nucleus of the arcopallium). B, summary of treatment 











Figure 3.2: Effects of unilateral lMAN lesion. 
Illustration of method used to confirm lMAN lesion of Nissl-stained parasagittal sections 












Figure 3.3: CBD improves vocal phonology in lesion animals.  
KL distance measures of phonology at four time points 45, 60, 75 and 90 days of their 
age was calculated. Treatment groups received 60 daily IM injections of either: VEH = 
vehicle once daily beginning at 30 days of age; CBD 30-40 = 10 mg/kg CBD from 30 to 
40 days of age and then vehicle to 90 days or; CBD 30-90 = 10 mg/kg CBD from 30 to 
90 days of age. A, KL distance measures of phonology for different treatment groups in 
unilateral lMAN lesion animals. All animals received unilateral lMAN lesions at age of 35 
days. At age 90 days, CBD 30-40 treatment significantly improved KL distance compared 
to VEH. Whereas, CBD 30-90 treatment did not significantly alter KL distance compared 
to VEH at all time points. B, KL distance measures of phonology for different lesion 
groups. All animals received 60 daily IM injections 10 mg/kg CBD from 30 to 40 days of 
age then vehicle to 90 days. At age 60 and 90 days, CBD 30-40 treatment significantly 
improved KL distance in lesion animals compared to no lesion. Whereas, CBD 30-40 
treatment did not significantly alter typical syllable transitions in sham animals compared 
to no lesion at all time points. Asterisk color indicates significant lesion group differences 






















































Figure 3.4: Sonogram examples of CBD effects on song in animals that received 
unilateral lMAN lesions 
All animals received a unilateral lMAN lesion at age of 35 days. sonograms shows good 
syntax and phonology for the animals were treated by CBD 30-40 for all four time points 










Figure 3.5:  Sonogram examples of CBD effects on song for animals received 
either unilateral lMAN lesion, sham or no lesion surgery.  
All animals received 10 mg/kg CBD from 30 to 40 days of age and then vehicle to 90 
days. Sonograms show good syntax and phonology for animals were received unilateral 










Figure 3.6: CBD speeds maturation of singing in lesion animals. 
Syntax quality measured through percent control typical syllable transitions at four time 
points 45, 60, 75 and 90 days of their age was calculated. The zebra finches received 60 
daily IM injections of either: VEH = vehicle once daily beginning at 30 days of age; CBD 
30-40 = 10 mg/kg CBD from 30 to 40 days of age and then vehicle to 90 days or; CBD 
30-90 = 10 mg/kg CBD from 30 to 90 days of age. A, Syntax quality was measured for 
different treatment groups in unilateral lMAN lesion animals. At age 45 days, CBD 30-40 
treatment significantly improved typical syllable transitions compared to VEH. Whereas, 
CBD 30-90 treatment did not significantly alter typical syllable transitions compared to 
VEH at all time points. B, Syntax quality was measured for different lesion groups. CBD 
30-40 treatment significantly improved typical syllable transitions in lesion animals 
comparing to no lesion. Whereas, CBD 30-40 treatment did not significantly alter typical 
syllable transitions in sham animals compared to no lesion at all time points. Asterisk color 
indicates significant lesion group differences determined by mixed-models post-hoc tests 








































































Figure 3.7: Effect of CBD on vocal output.  
Vocal output was measured by percent control singing per hour at four time points 45, 60, 
75 and 90 days of their age. Treatment groups received 60 daily IM injections of either: 
VEH = vehicle once daily beginning at 30 days of age; CBD 30-40 = 10 mg/kg CBD from 
30 to 40 days of age and then vehicle to 90 days or; CBD 30-90 = 10 mg/kg CBD from 
30 to 90 days of age. A, amount of singing was measured for different treatment groups 
in unilateral lMAN lesion animals. All animals received unilateral lMAN lesion at age of 35 
days. All treatments did not significantly alter %CTL singing per hour compared to VEH 
at all time points. B, amount of singing was measured for different lesion groups in animals 
received CBD 30-40. All lesion conditions did not significantly alter %CTL singing per hour 




































































CHAPTER 4: GENERAL CONCLUSION AND FUTURE DIRECTIONS 
The work in this dissertation was designed to accomplish two research goals: 1) 
to investigate the efficacy of CBD to improve learning-dependent vocal recovery following 
electrolytic destruction of a small part of a vocal motor brain region (HVC) which controls 
vocal production in adulthood, and; 2) to assess the effect of CBD to improve vocal 
learning after unilateral lesions of a vocal learning brain region (lMAN) which plays a major 
role during the sensorimotor stage of vocal learning. The central hypothesis was that CBD 
has distinct efficacy to mitigate CNS damage and promote vocal learning. 
Aim 1, the investigation of the effect of CBD to mitigate the effects of CNS damage 
in terms of vocal production was experimentally addressed in three steps: Firstly, 
establishing a new pre-clinical animal model for screening drugs for efficacy to improve 
vocal behavior. The HVC microlesion model succeeded as a model to assess and show 
the efficacy of CBD to improve vocal behavior comparing to untreated animals.  
Secondly, the ability of CBD to improve vocal learning following damage to lMAN 
that plays a major role in vocal learning during sensorimotor stage was examined. To test 
this, three different types of song analyses were measured: KL distances analysis was 
used to assess the effect of CBD to improve acoustic features, the sequence analysis 
was measured to investigate the ability of CBD to improve syntax and production analysis 
was used to assess vocal motor activity. Our results show that CBD treatment for a short 
period significantly has improved KL distance variability in adulthood time (not 
production). 
 Thirdly, was determined whether CBD produces these effects through interacting 




before receiving CBD to see whether the 5HT1A antagonist would reverse the CBD 
effects. Our results show that the mechanism of CBD to improve recovery and mitigate 
CNS damage include 5HT1A agonism, but likely other targets also involved. 
Aim 2 determined whether CBD has the ability to improve vocal learning following 
damage to the major circuit in sensorimotor learning stage, lMAN, that was addressed in 
two steps: Firstly, establishing a new pre-clinical animal model for screening drugs for 
efficacy to improve sensorimotor vocal learning. The unilateral lMAN lesion model 
succeeded in demonstrating the ability of CBD to improve vocal learning compared to 
untreated animals.  
Secondly, examining the efficacy of CBD to improve vocal learning. To test this, 
three types of song analyses were used: KL distances analysis was used to assess the 
effect of CBD to improve acoustic features, the sequence analysis was used to investigate 
the ability of CBD to improve syntax and production analysis was used to assess vocal 
motor activity. Our results show that CBD treatment sped maturation of singing in animals 
that received unilateral lMAN lesion in term of syntax and in term of phonology CBD 
improved KL distance variability in adulthood time. However, CBD does not have statically 
significant effect on vocal motor activity. 
Taken together, the research described in chapters 2 and 3 supports the central 
hypothesis that CBD has distinct efficacy to mitigate CNS damage and promote vocal 
learning. In addition, this project provides a valuable and great addition to the research 
through establishment of an important new animal model to screen drugs for efficacy to 
improve vocal learning and production; and provides a treatment that has an ability to 




Disruptions in speech and vocal communication are markers of several 
neuropsychiatric disorders, most remarkably autism spectrum disorders. Historically, 
animal models have been an effective approach for developing and examining disease-
relevant therapeutics. The unique aspects of human language when compared to vocal 
behaviors for other animals make finding a suitable animal model to examine the speech 
disorders potentially more challenging. In addition, the FDA requires at least the use of 
two animal models for any new therapeutic. To our knowledge this project provides the 
first animal model to screen drugs for efficacy to improve vocal learning and production. 
Songbirds are among the few vocal learning animals and the only examples well-suited 
to laboratory use (Petkov and Jarvis 2012). Zebra finches have many similarities to 
humans in-terms of vocal communication and production (as mentioned above) that make 
them a good candidate to assess effect of drugs having effects on CNS damage and 
processes of vocal learning. The targeting of HVC of this animal by electrolytic lesion (a 
small part about 9% of HVC) results in a temporary disruption of vocal patterns that 
recovers over about seven days (Thompson and Johnson, 2007). Recovery from these 
microlesions depends upon the ability of birds to hear, as deafened birds do not regain 
ability to produce typical song patterns (Thompson et al., 2007). Auditory dependence 
indicates that recovery of song requires auditory feedback that is part of sensorimotor 
learning. Thus, this pre-clinical animal (the songbird HVC microlesion) model will speed 
and open the closed door to assess drug effects upon both CNS damage and processes 
of vocal learning and this will help to discover a treatment for many people suffering from 




In addition to establishing a new and exclusively-useful pre-clinical animal model, 
the main finding of this project is to provide a promising drug for the treatment of speech 
and language disorders related to CNS trauma. Our findings show CBD has the ability to 
reduce the effects of HVC microlesions. This effect appears to involve both preventing 
deficits following HVC damage (secondary to tissue damage itself), and to a reduction in 
the amount of time required for recovery. These effects suggest that CBD reduces 
microlesion included deficits via interactions with processes secondary to tissue damage 
is based upon lack of significant differences across treatment groups in the amount of 
HVC destroyed (about 9% in all groups). Thus, the effect of CBD was not to reduce the 
size of the infarct. This indicates that disruptive effects of HVC microlesions must involve 
processes distinct from and secondary to the tissue damage itself. These secondary 
processes may include CBD-induced reductions in gliosis, metabolic derangement, 
excitotoxicity, neuroinflammation and/or protection of astrocyte function. These will be 
important to address in future studies. A proposed experiment may involve using proton 
magnetic resonance spectroscopy (H+-MRS) to assess the effect of CBD to reduce 
metabolic derangement (by measuring the ratio of lactate to N-acetylaspartate  in 
damaged tissue), excitotoxicity (by measuring the ratio of glutamate to N-
acetylaspartate), and protected astrocyte function (by measuring the ratio of myoinositol 
to creatine) after HVC microlesions. In addition, it is important to perform 
immunohistochemistry studies to assess ability of CBD to reduce neuronal loss and 
apoptosis (using TUNEL assay), astrogliosis (using an anti-GFAP antibody) and 
microglial proliferation (using an anti-Iba1 antibody). The results of these experiments will 




secondary to tissue damage. Whatever the secondary processes are, their mitigation 
improves ability of the songbirds to relearn to produce memorized vocal patterns. 
The ability of the songbirds to relearn after HVC microlesions depends upon the 
ability of birds to hear their songs. According to Thompson et al. deafened animals do not 
recover high-quality song because they don't receive the auditory feedback necessary for 
sensorimotor relearning (Thompson et al. 2007). It may also be important that the 
microlesion effect is restricted to motif syllables and does not appear to impair instinctive 
calls (Fig. 2C and D). Thus, CBD may prevents degradation of a learned behavior which 
consistent with findings of Karl et al that CBD improved memory in dementia models (Karl, 
Garner, and Cheng 2017) 
Additionally, previous work observed that birds subjected to lesions of lMAN prior 
to HVC microlesions exhibit no clear effect of the procedure (Thompson and Johnson 
2007). In addition, our results detected that CBD markedly reduced phonological 
disruptions after HVC microlesion. Again, this is intriguing given our microlesion target 
was HVC, a motor region most clearly associated with syntax-relevant syllable timing. 
Phonology looks more dependent upon the anterior forebrain circuit and its lMAN output 
to RA (Vu et al., 1994; Kao et al., 2005). This means that the ability of microlesions to 
disrupt vocalizations depends upon an intact lMAN, a simple potential mechanism for 
CBD to almost eliminate phonology disruptions might include interference with lMAN 
activity. Does CBD produce a pharmacological lMAN lesion? CBD inhibition of lMAN 
output is a hypothesis to be tested. To test this hypothesis quantitative EM techniques 




HVC and lMAN after receiving HVC microlesions and; CBD (or VEH). The ratio of 
HVC:lMAN derived synapses in RA increases during normal development because HVC 
is controlling RA in adult birds. We will test the hypothesis that exposure to CBD treatment 
after HVC microlesion will increase the ratio of HVC:lMAN by preventing or decreasing 
lMAN control over RA activity. If our hypothesis is true, this will indicate that exposure to 
CBD after a HVC microlesion that CBD produces a pharmacological lMAN lesion or 
inhibition of lMAN output and this will explain how CBD improves vocal learning after CNS 
damage. 
Moreover, Additional studies are needed to assess the effect of CBD on 
postoperative lesions through injecting CBD only after doing lesions. This has implications 
for potential therapeutic use of CBD in cases of CNS trauma that will likely depend upon 
after-incident administration. Finally, experiments assessing the accumulation of its 
metabolites in the brain and other organs after chronic administration will be important to 
understand more about its pharmacokinetics. 
Summary 
In this project: 
• Two pre-clinical models for screening drugs for efficacy to improve vocal behavior 
and vocal learning have been developed. 
• CBD improves recovery and reduces magnitude of CNS damage effects. 
• CBD improves sensorimotor relearning. 
• Mechanism of these effects may include, in-part, 5-HT1A agonism. 
• CBD improves vocal learning and appear to speed maturation of singing. 
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